Taisho Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taisho Pharmaceutical Co., Ltd., explained in plain language.
-
New hope for dialysis patients: drug trial targets dangerous phosphorus levels
Disease control Recruiting nowThis study tests an experimental drug called TS-172 in 100 adults on hemodialysis who have high phosphorus levels (hyperphosphatemia). Participants will take TS-172 or a placebo alongside their current phosphate binder medication. The goal is to see if TS-172 helps more patients …
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
New drug aims to help dialysis patients manage dangerous mineral levels
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of an investigational drug called TS-172. It is for adults on kidney dialysis who have high levels of phosphate in their blood, a common and serious problem. The goal is to see if TS-172 can safely help control these ph…
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New drug TS-172 tested in patients with liver disease
Knowledge-focused Recruiting nowThis study looks at how the drug TS-172 behaves in people with mild or moderate liver impairment. Researchers will measure drug levels in the blood to understand how the liver affects the drug. The study involves 24 Japanese adults and is currently recruiting participants.
Phase: PHASE1 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Apr 26, 2026 19:35 UTC